| Literature DB >> 30595538 |
Jinfang Zhang1, Ming Chen2, Yasheng Zhu3, Xiangpeng Dai1, Fabin Dang1, Junming Ren1, Shancheng Ren3, Yulia V Shulga4, Francisco Beca5, Wenjian Gan1, Fei Wu6, Yu-Min Lin7, Xiaobo Zhou8, James A DeCaprio9, Andrew H Beck1, Kun Ping Lu7, Jiaoti Huang10, Cheryl Zhao11, Yinghao Sun3, Xu Gao12, Pier Paolo Pandolfi13, Wenyi Wei14.
Abstract
Frequent SPOP mutation defines the molecular feature underlying one of seven sub-types of human prostate cancer (PrCa). However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa. Here, we report that SPOP suppresses stem cell traits of both embryonic stem cells and PrCa cells through promoting Nanog poly-ubiquitination and subsequent degradation. Mechanistically, Nanog, but not other pluripotency-determining factors including Oct4, Sox2, and Klf4, specifically interacts with SPOP via a conservative degron motif. Importantly, cancer-derived mutations in SPOP or at the Nanog-degron (S68Y) disrupt SPOP-mediated destruction of Nanog, leading to elevated cancer stem cell traits and PrCa progression. Notably, we identify the Pin1 oncoprotein as an upstream Nanog regulator that impairs its recognition by SPOP and thereby stabilizes Nanog. Thus, Pin1 inhibitors promote SPOP-mediated destruction of Nanog, which provides the molecular insight and rationale to use Pin1 inhibitor(s) for targeted therapies of PrCa patients with wild-type SPOP.Entities:
Keywords: Nanog; Pin1; PrCa; SPOP; phosphorylation; prostate cancer; stem cell; ubiquitination
Mesh:
Substances:
Year: 2018 PMID: 30595538 PMCID: PMC6462403 DOI: 10.1016/j.devcel.2018.11.035
Source DB: PubMed Journal: Dev Cell ISSN: 1534-5807 Impact factor: 12.270